Global
Austria
Japan
Belgium
Brazil
Netherlands
Portugal
Czech Republic
Spain
Denmark
Sweden
France
Germany
Taiwan
Ireland
United Kingdom
Italy
New 18-month findings evaluating Neurofilament light chain (NfL) as a potential biomarker of treatment response in patients with hATTR amyloidosis with polyneuropathy were presented at the 147th annual meeting of the American Neurological Association (ANA). Aldinc, et al. “NfL Levels Significantly Decrease in Response to Treatment...
We presented on platform and clinical results at the Oligonucleotide Therapeutics Society (OTS) 2022 18th Annual Meeting held in Phoenix, Arizona on October 2-5, 2022. Human Genetics as an Enabler of RNAi Therapeutics - Paul Nioi Phase 3 study, HELIOS-A, in hATTR Patients Evaluating a Single Dose...
At the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2022, we presented results from the APOLLO-B Phase 3 study of patisiran, an investigational RNAi therapeutic in development for the treatment of transthyretin-mediated (ATTR) amyloidosis with cardiomyopathy. Read the press release Maurer, et al. “Primary Results...
Results from a post-hoc analysis of patients on hemodialysis in the ongoing ILLUMINATE-C Phase 3 open-label study of lumasiran in patients with advanced primary hyperoxaluria type 1 (PH1) were presented at the International Pediatric Nephrology Association (IPNA) Congress (Sept. 7-11, 2022). Michael, et al. “Relationship of...